期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP4F2基因多态性与华法林维持剂量关系的研究进展 被引量：3

Research progress in association between CYP4F2 gene polymorphism and warfarin maintenance dose
原文传递
导出
摘要 华法林是目前临床上应用最广泛的口服抗凝药,其治疗安全范围窄,剂量个体差异大,临床应用中容易出现抗凝不当所致的并发症。近3年来,随着药物基因组学的快速发展,发现细胞色素P450酶4F2(CYP4F2)基因多态性(rs2108622)与华法林个体剂量差异相关。本文综述了近3年来在不同人种中进行的有关CYP4F2*3(rs2108622)与华法林的维持剂量关系的研究。大多数研究发现CYP4F2基因多态性与华法林维持剂量存在相关性,其中突变的T等位基因与华法林高剂量相关;CYP4F2*3可以解释1%～10%华法林剂量个体差异。 Currently,warfarin is the most widely used oral anticoagulant in clinic.Since warfarin has narrow therapeutic window and significant individual differences in dose,it easily leads to complications due to improper anticoagulate therapy.In recent 3 years,as the rapid development of pharmacogenomics,it has been found that CYP4F2（cytochrome P450,family 4,subfamily F,polypeptide 2） gene polymorphism（rs2108622） relates to warfarin individual dosage requirement.We reviewed research progress in association between CYP4F2 gene polymorphism.Most studies found that CYP4F2 gene polymorphism relates to warfarin dose,and the mutant T allele was associated with higher warfarin dose requirement,CYP4F2＊3 polymorphism can explain 1%~10% warfarin individual dosage difference.
作者 谢爽 李一石
机构地区 中国医学科学院北京协和医学院阜外心血管病医院卫生部心血管药物临床研究重点实验室
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第13期1183-1187,共5页 Chinese Journal of New Drugs
关键词 华法林 药物基因组学 CYP4F2 warfarin pharmacogenomics CYP4F2
分类号 R973.2 [医药卫生—药品]
  • 相关文献

参考文献32

  • 1WADELIUS M, PIRMOHAMED M. Pharmacogenetics of warfa- rin : current status and future challenges [ J ]. Pharmacogenomics J,2007,7(2) :99 - 111.
  • 2LIMDI NA, VEENSTRA DL. Warfarin pharmacogenetics [ J]. Pharmacotherapy, 2008,28 ( 9 ) : 1084 - 1097.
  • 3SCHELLEMAN H, LIMDI NA, KIMMEL SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics[J]. Pharmacogenomics, 2008,9(9) :1331 - 1346.
  • 4FDA. FDA approves updated warfarin(coumadin) prescribing information [ DB/OL]. ( 2007 - 08 - 16 ). http://www, fda. gov/bbs/topics/NEW S/2007/NEW01684. html.
  • 5CALDWELL MD, AWAD T, JOHNSON JA, et al. CYP2F2 ge- netic rariant alters required warfarin dose[ J]. Blood, 2008,111 (8) :4106 -4112.
  • 6LASKER JM, CHEN WB, WOLF I, et al. Formation of 20- hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eico- sanoid, in human kidney. Role of Cyp4F2 and Cyp4A11 [ J]. J Biol Chem, 2000,275 (6) :4118 - 4126.
  • 7POWELL PK, WOLF I, JIN R, et al. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by 17450 en- zymes in human liver: involvement of CYP4F2 and CYP4A11 [J]. J Pharmacol Exp Ther,1998,285( 3 ) :1327 - 1336.
  • 8SONTAG TJ, PARKER RS. Cytochrome P450 omega-hydroxy- lase pathway of tocopherol catabolism. Novel mechanism of regu- lation of vitamin E status [ J ]. J Biol Chem, 2002, 277 (28) : 25290 - 25296.
  • 9TEICHERT M, EIJGELSHEIM M, RIVADENEIRA F, et al. A genome-wide association study of acenocoumarol maintenance dosage[J]. Hum Mol Genet, 2009,18(19) :3758 -3768.
  • 10NCBI. GeneView via analysis of contig annotation: CYP4F2[ EB/ OL]. [2011 -04 -06]. http://www, ncbi. n|m. nih. gov/pro- jects/SNP/snp_ref, cgi? rs =2108622.

二级参考文献12

  • 1Borgiani P, Ci ccacci C, FORTE V, et al. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians [J]. Pharmacogenomics, 2007, 8 (11): 1545-50.
  • 2Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant ahers required warfarin dose [J]. Blood, 2008, 111(8): 4106-12.
  • 3LUO G, ZHENG L ZHANG X, et al. Genotyping of single nucleotide polymorphisms using base-quenched probe: a method does not invariably depend on the deoxyguanosine nucleotide[J].Anal Biochem, 2009, 386(2):. 161-6.
  • 4Li T, Chang CY, Jin DY, et al. Identification of the gene for vitamin K epoxide reductase [J]. Nature. 2004, 427, (6974): 541-4.
  • 5Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population [J]. Pharmacogenomics, 2009, 10(2): 261-6.
  • 6Stec DE, Roman R J, Flasch A, et al. Polymorphism in human CYP4F2 decreases 20-HETE production [J]. Physiol Genomics, 2007, 30(1): 74-81.
  • 7McDonald MG, Rieder M J, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant [J]. Mol Pharmacol. 2009, 75(6): 1337-46.
  • 8The International HapMap Project[J]. Nature, 2003, 426 (6968): 789-96.
  • 9Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORCI haplotype on transeriptional regulati on and warfarin dose [J]. N Engl J Med, 2005, 352(22):2285-93.
  • 10Bodin L, Verstuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2Cg) and vitamin K epoxide reduetase (VKORC1) genotypes as determinants of acenocoumarol sensitivity[J]. Blood 2005, 106(1): 135-40.

共引文献12

同被引文献65

  • 1唐和年,杜宇奎,张总刚,郭永忠,阿不拉江,郭盛,马中原,阿依别克,刘军,李明.新疆汉族和维吾尔族机械瓣膜置换术后低强度抗凝条件下华法林维持剂量与CYP2C9和VKORC1基因多态性的相关性研究[J].中国医药,2007,2(4):216-220. 被引量：7
  • 2Hirsh J,Fuster V,Ansell J. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy[J].Journal of the America College of Cardiology,2003,(09):1633-1652.
  • 3Lindh JD,Holm L,Dahl ML. Incidence and predictors of severe bleeding during warfarin treatment[J].Journal of Thrombosis and Thrombolysis,2008,(02):151-159.
  • 4Yin T,Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC 1-rationale and perspectives[J].Thrombosis Research,2007,(01):1-10.
  • 5Miao L,Yang J,Huang C. Contribution of age,body weight,and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin:proposal for a new dosing regimen in Chinese patients[J].EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,2007,(12):1135-1141.
  • 6Pirmohamed M. Pharmacogenetics:past,present and future[J].DRUG DISCOVERY TODAY,2011,(19-20):852-861.
  • 7Rettie AE,Wienkers LC,Gonzalez FJ. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9[J].PHARMACOGENETICS,1994,(01):39-42.
  • 8D'Andrea G,D' Ambrosio RL,Di Perna P. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin[J].Blood,2005,(02):645-649.
  • 9Rost S,Fregin A,Ivaskevicius V. Mutations in VKORC 1cause warfarin resistance and multiple coagulation factor deficiency type 2[J].NATURE,2004,(6974):537-541.
  • 10Gage BF,Lesko LJ. Pharmacogenetics of warfarin:regulatory,scientific,and clinical issues[J].Journal of Thrombosis and Thrombolysis,2008,(01):45-51.

引证文献3

二级引证文献13

中国新药杂志
2011年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部